By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals) 

Alexandria Center for Life Sciences
450 East 29th Street, 5th Floor
New York  New York  10016  U.S.A.
Phone: 212-308-6000 Fax: n/a




Company News
Kadmon Announces Supplemental Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease 7/25/2017 8:06:28 AM
Kadmon Announces Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease 7/11/2017 8:20:41 AM
Kadmon To Present Interim Data On KD025 In Chronic Graft-Versus-Host Disease (cGVHD) At R&D Day 6/23/2017 6:25:16 AM
Kadmon Announces Data Demonstrating The Potential Of The Company’s New GLUT Inhibitors For The Treatment Of Autoimmune And Inflammatory Conditions 6/1/2017 8:55:16 AM
Kadmon Provides Business Update And Reports First Quarter 2017 Financial Results 5/15/2017 8:22:55 AM
Kadmon To Present Clinical And Preclinical Data Highlighting The Role Of ROCK2 Signaling In Immune System Function At AAI Annual Meeting 5/11/2017 8:15:16 AM
Kadmon Announces Publication Of Clinical Data Showing KD025 Improved Clinical Scores In Psoriasis Patients 4/12/2017 11:46:22 AM
Kadmon Submits Second Abbreviated New Drug Application Filing For Trientine Hydrochloride To FDA 4/4/2017 7:55:33 AM
Kadmon Announces Amendment To Credit Agreement And Related Warrants 4/3/2017 8:09:37 AM
Kadmon Presents Preclinical Data Supporting The Therapeutic Potential Of ROCK Inhibition In Pulmonary Fibrosis 3/28/2017 8:40:20 AM